Double-blind, Placebo-controlled Study of BGC20-1531 in Migraine
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The study is being conducted to explore the safety and effectiveness of a new chemical
entity, BGC20-1531, in subjects with a history of migraine. In this study subjects will treat
a total of three migraine attacks with two different doses of BGC20-1531 and placebo, with at
least one week wash out period between doses.